Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gelofusine effect on 111In-exendin 4 renal uptake
NCT02541734Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Aug 2015
- Primary completion
- May 2017
- Modality
- Recombinant Proteins and Enzymes, Drug Delivery Systems
01
Overview
Phase 2, randomised trial of gelatin in diabetes mellitus (DM), insulinoma and congenital hyperinsulinism (HI) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Renal uptake of 111In-exendin-4 at 8 months. Started Aug 2015; status: completed.
02
Drugs
gelatin
03
Conditions
diabetes mellitus (DM)insulinomacongenital hyperinsulinism (HI)
Beyond the preview
Go deeper on NCT02541734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02541734.